GSA Capital Partners LLP Buys 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

GSA Capital Partners LLP raised its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 525.5% in the third quarter, HoldingsChannel reports. The fund owned 137,151 shares of the company’s stock after acquiring an additional 115,223 shares during the period. GSA Capital Partners LLP’s holdings in Aquestive Therapeutics were worth $683,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after purchasing an additional 1,353,518 shares during the period. Blue Owl Capital Holdings LP lifted its holdings in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $594,000. Deerfield Management Company L.P. Series C acquired a new position in shares of Aquestive Therapeutics in the second quarter valued at about $380,000. Finally, Chartwell Investment Partners LLC bought a new position in Aquestive Therapeutics during the third quarter worth about $535,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AQST shares. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partners lifted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.80.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $4.44 on Monday. The firm has a 50 day simple moving average of $4.99 and a two-hundred day simple moving average of $3.88. Aquestive Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.23. The company has a market cap of $404.84 million, a P/E ratio of -9.87 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period in the prior year, the business earned ($0.03) earnings per share. On average, analysts expect that Aquestive Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.